For HIV-1–negative, at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1. See full Indication.
APRETUDE was studied in 2 of the most diverse, comprehensive HIV-1 prevention trials to date. The separate trials (HPTN 083 and HPTN 084) included approximately 8000 participants from around the world in cooperation with the National Institute of Allergy and Infectious Diseases through the HPTN.1 Click below to see the trial design and efficacy and safety results.
Noninferiority international trial of cisgender men and transgender women who have sex with men and have evidence of high-risk behavior for HIV-1 infection. The trial included the prespecified ability to test for superiority
Superiority trial exclusively in cisgender women at risk of acquiring HIV-1
HPTN=HIV Prevention Trials Network; PrEP=pre-exposure prophylaxis.